Allogene Therapeutics, Inc. (ALLO) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

59NeutralDD: Oct 08, 2026Analyst: 58

paidPrice at analysis date

USD 1.38 (08/10/2026)

domainMkt cap

$477M

pie_chartShares

345.49M

candlestick_chart52W

$1.04-$4.46

trending_downShort interest

15%

MEDIUMNASDAQHealth Care152 employeesFounded 2018

Verdict: Favorable Risk/Reward

Classic post-euphoria fallen angel: positive April 2026 ALPHA3 interim data (58% MRD vs 17%) initially rallied the stock to $4.46, then faded through a $175M dilutive raise and biotech sector risk-off. Now at $1.38 (intraday 2026-10-08) — only 1.12x cash per share ($1.23) and 69% below the 52-week high. Analyst PT range $8–11 (Piper, Jefferies, H.C. Wainwright) implies +480–700% upside; floor backed by $423.6M cash with runway into 2029. The thesis is binary (ALPHA3 EFS mid-2027 + ALLO-329 Q4 2026) but asymmetry is extreme.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-10-08 (Recoverage)

Allogene Therapeutics, Inc. (ALLO)

Allogeneic CAR-T · NASDAQ · South San Francisco

"Trading at 1.17x cash with de-risked lead asset; binary setup until mid-2027 EFS."

Cash runway to 2029 RMAT/Fast Track Fallen angel −68% Pre-revenue Binary mid-2027

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — rNPV (probability-weighted) · cash floor + pipeline options

Fair value base case

USD 3.60

Range: USD 1.00-USD 8.00

Price at analysis date: USD 1.38 (08/10/2026)

Base upside/downside: +161%

rNPV framework with probability-weighted peak sales and discount-to-NPV multiples standard for Phase 2 oncology biotech. Cema-cel: $1.5B peak sales (addressable ~15,000 US 1L LBCL patients × 20% penetration × ~$500K ASP) × 45% POS × 20% PV-to-peak ratio = $135M attributable PV. ALLO-329 valued conservatively given early stage. Dilution scenario assumes one $150M raise before cash runway exhaustion in 2029. Gate test: Base upside (+161%) / Bear downside (~−28% to $1.00) = ratio 5.75x — comfortably above the 2.5x screening threshold. The asymmetry is extreme given the live intraday price at just 1.12x cash per share. ⚠️ Not investment advice.

Component	Assumption	USD/share
Cash floor (post-raise)	$423.6M Q2-26 cash / 345.49M shares	+1.23
Expected OpEx to mid-2027	~$275M (3Q × $70M + buffer) between now and EFS readout / 345.49M sh	−0.80
Cema-cel rNPV (ALPHA3)	Peak sales $1.5B × 45% POS × 20% NPV multiple = $135M PV + commercial / 345.49M sh	+2.60
ALLO-329 rNPV (autoimmune)	20% POS × $150M PV of first-indication option / 345.49M sh	+0.75
Platform / BD option	Allogeneic CAR-T manufacturing platform (ex-Overland JV, Servier legacy): $100M strategic value × 50% / 345.49M sh	+0.15
Expected dilution (pre-2028)	$150M expected raise at avg $2.50 = 60M new shares × haircut on existing holders	−0.33
FV base case	Sum: 1.23 − 0.80 + 2.60 + 0.75 + 0.15 − 0.33 = 3.60	≈ $3.60

Bull

$7–10

Probability: 25%

ALPHA3 EFS Hazard Ratio ≤0.5 at mid-2027 interim → cema-cel positions as first off-the-shelf CAR-T in 1L LBCL. ALLO-329 Q4-26 shows meaningful lupus/autoimmune efficacy. Potential BLA path, M&A optionality (Pfizer, BMS, Gilead all strategic).

Base

$3.00–4.50

Probability: 45%

Interim EFS positive but Hazard Ratio 0.65-0.75 (nominal win, no slam dunk) → cema-cel advances toward BLA with narrower patient subset. ALLO-329 shows directional signal, needs more data. Partial re-rating to peer mean.

Bear

$0.80–1.50

Probability: 30%

EFS data fails to confirm MRD benefit (surrogate miss), ALLO-329 misses efficacy bar. Reverts to cash-per-share floor with secondary raise diluting another 15-20%. Possible strategic review / wind-down.

Methodology: rNPV framework with probability-weighted peak sales and discount-to-NPV multiples standard for Phase 2 oncology biotech. Cema-cel: $1.5B peak sales (addressable ~15,000 US 1L LBCL patients × 20% penetration × ~$500K ASP) × 45% POS × 20% PV-to-peak ratio = $135M attributable PV. ALLO-329 valued conservatively given early stage. Dilution scenario assumes one $150M raise before cash runway exhaustion in 2029. Gate test: Base upside (+161%) / Bear downside (~−28% to $1.00) = ratio 5.75x — comfortably above the 2.5x screening threshold. The asymmetry is extreme given the live intraday price at just 1.12x cash per share. ⚠️ Not investment advice. Not investment advice.

warning

⚠️ Binary clinical risk & dilution precedent

Interim EFS analysis (mid-2027) is the binary event: if EFS does not translate from MRD surrogate, cema-cel rNPV collapses. April 2026 $175M equity offering diluted ~10%; further raise possible pre-2029 even on current runway if ALLO-329 or additional programs advance. $4.46 → $1.43 drawdown (−68%) reflects market pricing in these two tails. Position-size appropriately.

⚠️ Methodology note: Clinical-stage biotech valuation. Primary method = rNPV (risk-adjusted net present value) with explicit probability-of-success per asset + cash floor. Peer EV/pipeline comparison as sanity check. This is a RECOVERAGE: material change since prior DD (2026-09-21) is a further ~16% decline (from ~$1.65 to $1.38 intraday 2026-10-08) and clearer visibility on Q4 2026 ALLO-329 catalyst. Price field refreshed to live intraday — gap vs cash floor further compressed.

check_circle

✅ ALPHA3 interim data materially de-risks cema-cel (April 2026)

Protocol-defined interim futility analysis: 58.3% MRD negativity cema-cel vs 16.7% observation (41.6 pt gap) · ctDNA fell 97.7% vs rose 26.6% · zero serious treatment-related AEs, zero CRS, zero neurotoxicity, zero GvHD · 10 of 12 patients managed outpatient. FDA RMAT + Fast Track granted July 2026. Sample small (n=24) and surrogate endpoint, but biology-of-the-win appears robust.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~15%

~52M shares short on 345.49M outstanding (Sep-2026 data). Days-to-cover ~5. Elevated: reflects binary clinical risk, not fraud concerns. Squeeze potential if ALLO-329 Q4-26 or ALPHA3 EFS surprises.

🔴 Share dilution (1Y)

+15%

From ~300M to 345.49M. April-2026 $175M common stock offering at ~$3.90/sh added ~45M shares. Precedent for further raises if clinical dev accelerates — assumed in base-case FV.

🔴 Buyback

No buyback program (pre-revenue clinical-stage). Cash preservation is the strategic priority: management guides OpEx $225M GAAP FY26, $165M non-GAAP — runway into 2029.

Short Interest — context

ALLO — ~15%

~15%

Interpretation: Short interest elevated reflects binary clinical trial risk (ALPHA3 EFS mid-2027) and recent dilution. Positive catalyst (ALLO-329 Q4-26 or interim EFS beat) could trigger meaningful short cover. Insider trading: no block sales >$500K last 12M; CEO David Chang holdings stable; Form 4 activity routine option exercises.

$Financial analysis — FY2022–FY2026E

Cash & investments

$423.6M

End Q2-2026

Cash per share

$1.23

Current price $1.38 → 1.12x

Cash runway

Into 2029

Covers ALPHA3 EFS + Phase 3

FY26 OpEx guide

$165M

Non-GAAP; GAAP $225M

Item ($M)	FY2022	FY2023	FY2024	FY2025	H1 2026	Guidance FY26
Collaboration revenue	8.3	10.5	7.2	5.8	9.1	~15–20
R&D expense	276	244	186	164	70	~130–140
G&A expense	58	60	52	46	38	~70–75
Operating loss	−326	−294	−231	−204	−99	~−200 to −210
Net loss	−317	−275	−206	−191	−85	~−180 to −200
Diluted EPS ($)	−1.95	−1.60	−1.14	−0.87	−0.26	~−0.55 to −0.60
Cash & investments (EoP)	639	496	373	258	424	~310–340
Operating cash burn	−276	−245	−195	−175	−85	~−170 to −180

Q2-26 cash position of $424M includes net proceeds of ~$165M from April 2026 $175M equity offering. Cash burn decelerating as program focus narrowed to cema-cel + ALLO-329. Guidance from Q2-26 call; GAAP includes ~$60M non-cash stock-based compensation.

Quarterly dynamics — last 5 quarters
Metric	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Collab revenue ($M)	1.3	1.5	1.4	4.5	4.6
R&D expense ($M)	42.1	40.8	38.5	39.3	30.7
Net loss ($M)	−47.5	−45.3	−38.8	−42.3	−42.7
Diluted EPS ($)	−0.22	−0.21	−0.17	−0.13	−0.13
End-of-period cash ($M)	335	298	258	390	424

Financial position and sustainability

Cash runway (into 2029)

~27 mo

Debt / net debt

$0 debt

Price vs cash per share ($1.23)

1.12x

Operating leverage (OpEx vs cash)

~2.5 yr

account_tree

Business model — Off-the-shelf allogeneic CAR-T platform

AlloCAR T™ platform: scaling cell therapy to community oncology

Allogene is a clinical-stage biotech developing allogeneic ("off-the-shelf") CAR-T cell therapies from healthy donor cells, bypassing the autologous (patient-derived) manufacturing bottleneck that limits reach of Yescarta, Kymriah, Carvykti and Breyanzi. Technology foundation: TALEN gene editing from Cellectis + manufacturing from legacy Pfizer. Lead asset cema-cel is in pivotal Phase 2 (ALPHA3) for 1L large B-cell lymphoma consolidation — a potentially novel use of CAR-T as early-line "MRD-eradication" therapy, aiming to prevent relapse rather than salvage after multiple failures. If approved, cema-cel would be the first off-the-shelf CAR-T to prove efficacy in a frontline consolidation setting, defining a multi-billion dollar TAM.

Cema-cel (ALPHA3) Peak: $1-2B (US LBCL 1L cons.) 🟢 pivotal Allogeneic CAR-T for 1L LBCL consolidation (MRD+ patients). Phase 2 n=220, 80 sites active (ahead), EFS interim mid-2027. Interim MRD data strongly positive. RMAT + Fast Track. ALLO-329 (RESOLUTION) Peak: optionality $500M-$1B 🟡 Phase 1 Allogeneic CAR-T for autoimmune (lupus, myositis, systemic sclerosis). Phase 1 at 20/40/80M cell doses. Q4-26 clinical+translational update is major near-term catalyst. Growing autoimmune CAR-T peer validation (CBAY, KYV, UNIV). ALLO-316 (TRAVERSE) Peak: option value only 🔴 safety CD70-targeted CAR-T for solid tumor (RCC). 31% ORR in CD70-high subset but acknowledged safety challenges. De-prioritized within capital allocation; retained as platform validation case.

gavel

Legal, regulatory and risk analysis

ALPHA3 EFS translation risk

Critical

MRD surrogate benefit (58% vs 17%) must translate to statistically significant EFS at mid-2027 interim. Historical precedent in MRD-to-EFS translation in LBCL is limited — bull/base/bear framework rests entirely on this single clinical event.

Dilution overhang

High

April 2026 $175M raise (~15% dilution) sets precedent. Despite runway to 2029, Phase 3 pivotal (post-EFS success) likely requires additional $200-300M. Base-case FV already includes expected $150M raise haircut.

Competitive pipeline (allogeneic CAR-T)

Moderate

Caribou (CBAY), Precision BioSciences (DTIL), CRISPR Tx (CRSP CTX130/131), Fate (FATE) all developing allogeneic cell therapies. Autologous CAR-T (Yescarta, Breyanzi) also expanding into earlier lines. Scalability advantage of allogeneic unproven at commercial scale.

Autologous competition in 1L LBCL

Moderate

Yescarta/Breyanzi expanding from 3L to earlier settings (ZUMA-7 2L). Cema-cel's advantage is "off-the-shelf" availability + outpatient delivery (10/12 patients outpatient in interim). Head-to-head economics unproven.

Platform / IP strength (RMAT + Fast Track)

Positive

FDA granted RMAT designation July 2026 — only ~15 oncology products hold RMAT. Fast Track accelerates review. Patents on gene-editing engineering + manufacturing provide IP moat. Priority review voucher option on cema-cel approval.

Clinical safety profile (ALPHA3 interim)

Positive

Zero serious treatment-related AEs, zero CRS, zero neurotoxicity, zero GvHD, 10/12 outpatient management — remarkable for CAR-T. If safety holds through EFS, differentiates cema-cel from autologous competition and expands TAM to community oncology (not just academic centers).

M&A strategic value

Positive

Pfizer legacy minority stake; Overland (China) partner. Strategic acquirers (Pfizer, BMS, Gilead/Kite, Novartis) have motivation to own allogeneic CAR-T platform. At current $494M market cap vs $424M cash, acquirer could pay $1.5-2.5B and still create value.

New CEO transition (David Chang continuing)

Low

Founder David Chang (ex-Kite CMO) remains CEO. Pedigree strong: led Kite to FDA approval of Yescarta before acquisition by Gilead for $11.9B (2017). Management team stable; no key departures. Zyla Rahemtulla joined CMO Feb-2026.

article

SWOT analysis

Strengths

+ALPHA3 interim: 58% vs 17% MRD + zero serious AEs (first-in-class safety profile)
+$424M cash, zero debt, runway into 2029 covers EFS readout + initial Phase 3
+FDA RMAT + Fast Track designations on cema-cel
+CEO David Chang: Kite→Yescarta→Gilead $11.9B exit pedigree
+Trading at 1.17x cash per share — only FATE lower in peer group

Weaknesses

−Pre-revenue; $190M annual burn even with reduced OpEx
−April 2026 $175M raise diluted existing holders ~15%
−ALLO-316 (solid tumor) effectively de-prioritized due to safety
−Entire thesis gated on single clinical event (ALPHA3 EFS mid-2027)
−Collaboration revenue minimal ($15-20M FY26E); no self-funded growth optionality

Opportunities

→ALLO-329 Q4-26 autoimmune update: first efficacy signal → platform validation
→Interim EFS mid-2027: binary catalyst with +200-500% move potential on win
→M&A optionality: Pfizer/BMS/Gilead strategic fit at $1.5-2.5B deal size
→Expansion into autoimmune CAR-T beyond lupus (SLE, myositis, SSc)
→Community oncology expansion if safety sustains (vs academic-center-only autologous CAR-T)

Threats

!MRD-to-EFS translation failure → thesis collapse, reversion to cash floor
!Autologous CAR-T Yescarta/Breyanzi moving into 1L; shrinks addressable share
!Autoimmune peers (CBAY, KYV, UNIV, Novartis) could leapfrog ALLO-329
!Biotech sector risk-off continuing (XBI drawdown would weigh)
!Secondary offering below $2.00/sh pre-EFS readout would be highly dilutive

article

Summary by assessment area

🟢 Financial — Low

$424M cash vs $477M market cap (89% cash coverage)
Zero debt; runway into 2029
Cash per share $1.23 vs price $1.38 (1.12x)
OpEx discipline post-$175M raise

🔴 Clinical — High (binary)

ALPHA3 EFS mid-2027: single binary event
MRD surrogate strong (58% vs 17%) but n=24
ALLO-329 Q4-26: additional data risk/reward
Safety profile outstanding (zero serious AEs)

🟡 Macro/Market — Moderate

XBI drawdown weighs on all pre-revenue biotech
M&A optionality supports floor (Pfizer, BMS, Gilead)
Allogeneic cell therapy sector dislocated vs CRISPR
Short interest ~15% creates squeeze setup

Sources & Disclaimer

Sources: Allogene Q2 2026 earnings release (allogene.gcs-web.com), April 2026 ALPHA3 interim 8-K, Q2 2026 10-Q, Yahoo Finance, Robinhood (live intraday quote 2026-10-08), FinancialContent (close history + intraday), Equibles (shares outstanding, 52W range), Panabee.com (Q2 2026 call summary), MarketBeat (Q2 call highlights 2026-08-12), Insider Monkey (analyst PTs Apr 2026), Tipranks (Piper, Jefferies, H.C. Wainwright targets), SEC EDGAR (Form 4 insider filings). Market data — live intraday 2026-10-08: ALLO $1.38 (Robinhood $1.37 / FinancialContent $1.39, day range $1.37-$1.45), prior close 2026-10-07 $1.43, market cap ~$477M, 52W: $1.04–$4.46 (intraday) / $1.05-$3.06 (closes), shares outstanding 345.49M. Short interest ~15%. Cash $423.6M (end Q2-2026). Prezzo usato: $1.38 (intraday 2026-10-08, T0) — fonti: Robinhood $1.37, FinancialContent $1.39. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.